Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lovastatin in primary hypercholesterolemia. A Norwegian multicenter study].

L Ose1

  • 1Lipidklinikken, Rikshospitalet, Oslo.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 30, 1992
PubMed
Summary

Lovastatin effectively lowers cholesterol in hypercholesterolemia patients. Combination therapy with cholestyramine may be needed for severe cases to reach target cholesterol levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Double-Blind Comparison of the Efficacy and Tolerability of Simvastatin and Fluvastatin in Patients with Primary Hypercholesterolaemia.

Clinical drug investigation·2016
Same author

Erratum to Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia.

Clinical drug investigation·2016
Same author

Oxidized LDL level is related to gene expression of tumour necrosis factor super family members in children and young adults with familial hypercholesterolaemia.

Journal of internal medicine·2012
Same author

Paediatric screening for hypercholesterolaemia in Europe.

Archives of disease in childhood·2011
Same author

A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet.

International journal of clinical practice·2007
Same author

Enhanced platelet activation in hyperhomocysteinemic individuals.

Journal of thrombosis and haemostasis : JTH·2006

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Primary hypercholesterolemia is a significant risk factor for cardiovascular disease.
  • Effective lipid-lowering therapies are crucial for managing this condition.
  • Assessing the efficacy and safety of HMG-CoA reductase inhibitors like lovastatin is important.

Purpose of the Study:

  • To evaluate the safety, tolerability, and plasma lipid effects of lovastatin in patients with primary hypercholesterolemia.
  • To determine the efficacy of lovastatin monotherapy and combination therapy with cholestyramine.
  • To assess the achievement of target cholesterol levels in a large patient cohort.

Main Methods:

  • A 48-week, multi-center study involving 266 patients with primary hypercholesterolemia.

Related Experiment Videos

  • Lovastatin was administered at doses ranging from 20 to 80 mg/day.
  • Combination therapy with cholestyramine was optionally initiated at week 13 for non-responders.

    • Main Results:

    • Lovastatin treatment resulted in significant reductions in total cholesterol (-34%), LDL-cholesterol (-42%), and triglycerides (-14%), with a notable increase in HDL-cholesterol (+14%) after 12 weeks.
    • After 48 weeks, only 25% of patients achieved a total cholesterol below 5.2 mmol/l, while 60% reached below 6.2 mmol/l.
    • The study reported good tolerability, with only four dropouts due to adverse events, three possibly related to lovastatin. One case of myositis was observed.

    Conclusions:

    • Lovastatin demonstrates significant efficacy in reducing plasma lipids in patients with primary hypercholesterolemia.
    • Combination therapy with lovastatin and cholestyramine is necessary for achieving target cholesterol levels (<5.2 mmol/l) in patients with severe hypercholesterolemia.
    • Lovastatin is generally well-tolerated, but careful monitoring for adverse effects, including myositis, is warranted.